linopirdine has been researched along with Acute Confusional Senile Dementia in 10 studies
linopirdine: acetylcholine releasing drug
| Excerpt | Relevance | Reference |
|---|---|---|
| "Small differences in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores were seen throughout the study favouring linopirdine; at 6 months the ADAS-Cog scores were 20." | 2.68 | A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. ( Beattie, BL; Eastwood, MR; Feldman, H; Gauthier, S; Mohr, E; Pryse-Phillips, W; Rockwood, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkerson, WW | 1 |
| Kergaye, AA | 1 |
| Tam, SW | 3 |
| Earl, RA | 2 |
| Zaczek, R | 4 |
| Teleha, CA | 1 |
| Fisher, BN | 2 |
| Maciag, CM | 2 |
| Marynowski, ME | 1 |
| Logue, AR | 2 |
| Tinker, WJ | 1 |
| Huang, SM | 1 |
| Chorvat, RJ | 2 |
| Provan, SD | 1 |
| Miyamoto, MD | 1 |
| Kim, YS | 1 |
| Nibbelink, DW | 1 |
| Overall, JE | 1 |
| Aiken, SP | 1 |
| Brown, BS | 1 |
| Rockwood, K | 1 |
| Beattie, BL | 1 |
| Eastwood, MR | 1 |
| Feldman, H | 1 |
| Mohr, E | 1 |
| Pryse-Phillips, W | 1 |
| Gauthier, S | 1 |
| van Dyck, CH | 1 |
| Lin, CH | 1 |
| Robinson, R | 1 |
| Cellar, J | 1 |
| Smith, EO | 1 |
| Nelson, JC | 1 |
| Arnsten, AF | 1 |
| Hoffer, PB | 1 |
| Saye, JA | 1 |
| Pierdomenico, ME | 1 |
| Rominger, DH | 1 |
| DeNoble, VJ | 1 |
| DeNoble, KF | 1 |
| Spencer, KR | 1 |
1 review available for linopirdine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Pharmacology of the neurotransmitter release enhancer linopirdine (DuP 996), and insights into its mechanism of action.
Topics: Alzheimer Disease; Drug Interactions; Electrophysiology; Indoles; Pyridines | 1996 |
3 trials available for linopirdine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Factor structure and scoring of the SKT test battery.
Topics: Aged; Alzheimer Disease; Attention; Double-Blind Method; Humans; Indoles; Mental Recall; Neuropsycho | 1993 |
A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Indoles; | 1997 |
The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebrovascular Circulation; Female; Humans; Indoles; Male; | 1997 |
6 other studies available for linopirdine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
3-Substituted, 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones as acetylcholine release enhancers: synthesis and SAR.
Topics: Acetylcholine; Alzheimer Disease; Amnesia; Animals; Avoidance Learning; Corpus Striatum; Hypoxia; In | 1993 |
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
Topics: Acetylcholine; Alzheimer Disease; Animals; Anthracenes; Drug Evaluation, Preclinical; Hippocampus; I | 1998 |
Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Indoles; Membrane Potentials; Molecular Structure; Neu | 1995 |
Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.
Topics: 4-Aminopyridine; Acetylcholine; Alzheimer Disease; Animals; Calcium; Dose-Response Relationship, Dru | 1994 |
Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.
Topics: Acetylcholine; Alzheimer Disease; Animals; Anthracenes; Dose-Response Relationship, Drug; Indoles; M | 1998 |
Protection against hypoxia-induced passive avoidance deficits: interactions between DuP 996 and ketanserin.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Drug Interactions; Hypoxia; Indoles; Ketanserin; Mal | 1991 |